Incyte Corp

21 de jul. de 2026, 16:36 UTC

HC Wainwright reiterated its Buy rating on Incyte Corp with a $140 price target, contributing to gains in Incyte shares during Tuesday's session.

20 de jul. de 2026, 21:56 UTC

Incyte Corp shares are lower in after-market hours following a volatile session, despite trading above the 20-day moving average and near a one-month high.

17 de jul. de 2026, 23:16 UTC

Incyte Corp shares are higher in after-market trading, continuing a trend of five consecutive sessions of gains. No specific news was identified for the movement.

16 de jul. de 2026, 23:06 UTC

Incyte Corp shares are trading lower in after-market hours amid a broader market decline, influenced by rising interest rates and geopolitical tensions.

15 de jul. de 2026, 19:16 UTC

Incyte Corp remains elevated above its 20-day moving average, recently surpassing Weyerhaeuser to become the 400th largest company in the S&P 500.

13 de jul. de 2026, 16:21 UTC

Incyte Corp shares are lower amid concerns over revenue guidance despite positive Phase 1/2 data for latarcibart presented at ISTH 2026 Congress.

10 de jul. de 2026, 20:06 UTC

Incyte Corp's shares are lower today, influenced by declines in the Biotechnology sub-sector. The stock peaked early before steadily declining throughout the session.

9 de jul. de 2026, 23:56 UTC

Incyte Corp shares are lower in after-market hours amid broader market caution linked to renewed military tensions between the U.S. and Iran.

8 de jul. de 2026, 20:04 UTC

Incyte Corp shares are lower as biotechnology stocks face pressure. The broader sector's significant losses have impacted Incyte's performance today.

7 de jul. de 2026, 23:06 UTC

Incyte Corp shares are lower in after-market hours amid a broader market decline. No specific company news has been identified to influence the price.

6 de jul. de 2026, 23:01 UTC

Incyte Corp shares are higher in after-market trading, approaching the upper end of their one-month trading range. No specific news was identified for this movement.

3 de jul. de 2026, 00:01 UTC

Incyte Corp shares are lower in after-market hours, with no specific news identified. Broader market conditions may be influencing investor sentiment.

2 de jul. de 2026, 23:01 UTC

Incyte Corp shares declined in after-market hours amid notable volatility, contrasting with three consecutive sessions of gains. No specific news was identified for the move.

1 de jul. de 2026, 21:01 UTC

Incyte Corp shares are higher in after-market trading, reflecting a notable increase as they approach the upper end of their one-month range.

30 de jun. de 2026, 23:01 UTC

Incyte Corp shares are higher in after-market trading, maintaining an upward trend despite broader market declines, particularly in the tech sector.

29 de jun. de 2026, 23:16 UTC

Incyte Corp shares are higher in after-market trading following positive results from the Phase 2b trial of EVO756 for chronic spontaneous urticaria.

26 de jun. de 2026, 23:51 UTC

Incyte Corp shares are higher in after-market trading following a positive recommendation for Opzelura® cream from the European Medicines Agency's Committee for Medicinal Products.

25 de jun. de 2026, 23:51 UTC

Incyte Corp shares are higher in after-market hours, recovering from an earlier session low. Broader market performance remains mixed amid varying tech stock results.

24 de jun. de 2026, 20:02 UTC

HC Wainwright reiterated its Buy rating on Incyte Corp with a $140 price target, contributing to the stock's advance amid positive social media sentiment.

23 de jun. de 2026, 19:46 UTC

Incyte Corp shares are higher today, reflecting a cumulative gain since Monday. The stock has rebounded from an earlier session pullback amid broader market pressures.

22 de jun. de 2026, 20:02 UTC

Incyte Corp's stock is higher after Japan approved Minjuvi for lymphoma treatment. BMO upgraded the company to Market Perform and raised its price target to $94.

18 de jun. de 2026, 22:16 UTC

Incyte Corp shares are trading higher in after-market hours. No specific news was identified to explain this movement amid a broader market uptrend.

17 de jun. de 2026, 23:46 UTC

Incyte Corp shares are lower in after-market trading following significant volatility. Broader market trends may be affecting investor sentiment amid stronger U.S. retail sales.

16 de jun. de 2026, 19:22 UTC

Incyte shares are lower despite positive phase II study results for zilurgisertib. The FDA has begun Priority Review of the New Drug Application.

15 de jun. de 2026, 14:23 UTC

Incyte Corp's stock is lower as analysts raise concerns over clinical data despite promising Phase 3 trial results for tafasitamab.

12 de jun. de 2026, 22:02 UTC

Incyte Corp shares are lower in after-market hours, continuing a trend of unusual weakness since Friday's close, with no specific news identified.

11 de jun. de 2026, 22:02 UTC

Incyte Corp shares are lower in after-market hours, despite being above their 20-day moving average and three consecutive sessions of higher closes.

10 de jun. de 2026, 21:02 UTC

Incyte shares rise in after-market trading on Guggenheim target increase.

9 de jun. de 2026, 20:02 UTC

Incyte Corp gains as HC Wainwright raises price target to $140 and the company announces a $1.25 billion acquisition of Vega Therapeutics.

8 de jun. de 2026, 19:42 UTC

Incyte Corp shares are lower after announcing a $1.25 billion acquisition of Vega Therapeutics, which will impact upcoming financial results significantly.